Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present 18-month data results from its ongoing HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD). These recent updates will be presented on a webinar, hosted with the nonprofit organization, Parent Project Muscular Dystrophy (PPMD), on Wednesday, January 25, 2023 at 1:00 p.m. ET. To listen to the webinar, please click the following link: http://join.parentprojectmd.org/webinar. For additional details on the webinar, please visit www.parentprojectmd.org. A replay of the webinar will be made available on PPMD’s website. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow the Company on Facebook, Instagram and Twitter. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams and revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on March 11, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on November 10, 2022. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Capricor Media Contact:Raquel ConaKCSA Strategic [email protected] Capricor Investor Contact:Joyce AllaireLifeSci Advisors, [email protected] Capricor Company Contact:AJ Bergmann, Chief Financial [email protected]